期刊文献+

万拉法辛缓释剂与帕罗西汀治疗广泛性焦虑障碍的对照研究 被引量:4

Controlled study of generalized anxiety disorder with venlafaxine extended release and paroxetine
下载PDF
导出
摘要 目的研究万拉法辛缓释剂与帕罗西汀治疗广泛性焦虑障碍的疗效与安全性。方法根据DSM-IV诊断标准将广泛性焦虑障碍患者随机分成2组,万拉法辛缓释剂治疗组(25例)和帕罗西汀治疗组(23例),均治疗8周;采用HAMA、CGI-SI评定疗效;采用TESS、实验室检查及体查评价安全性。结果HAMA、CGI-SI量表分在治疗过程中显著下降,2组疗效相当,均未有严重不良事件发生。结论万拉法辛缓释剂与帕罗西汀是安全有效的治疗广泛性焦虑障碍的药物,患者对药物的耐受性及依从性好。 Objective To evaluate the efficacy and tolerability of venlafaxine extended release(XR) and paroxetine for patients with generalized anxiety disorder(GAD).Methods Twenty-five patients who met DSM-IV criteria for GAD were randomly assigned to venlafaxine XR and another 23 patients to paroxetine and the treatment lasted 8 weeks.Efficacy was assessed with the Hamilton Rating Scale for Anxiety(HAMA) and Clinical Global Impression of Illness(CGI-SI) scale.Safety was evaluated by TESS,laboratory and physical examination throughout the study.Results The scores showed a significant decrease over time in both groups.Effects of both groups were similar.There were no serious adverse events in both groups.Conclusion Either venlafaxine XR or paroxetine would be effective and tolerable for patients with GAD.
出处 《中南药学》 CAS 2009年第11期863-866,共4页 Central South Pharmacy
关键词 广泛性焦虑障碍 万拉法辛缓释剂 帕罗西汀 耐受性 generalized anxiety disorder venlafaxine extended release paroxetine tolerability
  • 相关文献

参考文献12

  • 1Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [J]. Arch Gen Psychiatry, 2005, 62 (6): 617-627.
  • 2Rodriquez BF, Weisberg RB, Pagano ME, et al. Characteristics and predictors of full and partial recoveryfrom generalized anxiety disorder in primary care patients[J].Nerv Ment Dis, 2006, 194 (2): 91-97.
  • 3Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder [J].Biol Psychiatry , 2002 , 51 (1) : 109- 120.
  • 4Rudolph RL, Entsuah R. A Meta-analysis of the effects of venlafaxine on anxiety associated with depression [J]. J Clin Psy chopharmacol, 1998, 18 (2): 136-44.
  • 5Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine [J]. J. Clin Psychiatry, 2004, 65 (12), 1696-1707.
  • 6Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebocontrolled study [J]. Am. J. Psychiatry, 2003, 160 (4): 749-756.
  • 7Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extend ed-release venlafaxine in nondepressed outpatients with general ized anxiety disorder [J].Am J Psychiatry, 2000, 157: 968-974.
  • 8Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebocontrolled, flexible-dosage trial [J].J. Clin Psychiatry, 2001, 62 (5): 350-357.
  • 9Kim TS, Pae CU, Yoon SJ, et al. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder [J].Psychiatry Clin Neurosci, 2006, 60 (3): 317-351.
  • 10Feighner JP. Cardiovascular safely in depressed patients: focus on venlafaxine [J].J Clin Psychiatry, 1995 , 56 (12): 574-579.

同被引文献34

  • 1司天梅,舒良.关于新抗抑郁药艾司西酞普兰[J].临床精神医学杂志,2007,17(1):68-69. 被引量:124
  • 2Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Repli- cation[J]. Arch Gen Psychiatry,2005, 62(6): 593 -602.
  • 3Ma X, Xiang YT, Cai ZJ, Generalized anxiety dis order in China: prevalence, sociodemographic corre lares, comorbidity, and suicide attempts[J]. Per spect Psychiatr Care , 2009,45(2):119-127.
  • 4Davidson JR, Zhang W, Connor KM, et al. A psy chopharmacological treatment algorithm for gener alised anxiety disorder (GAD) [J]. J Psychophar macol,2008,10(2) :1-24.
  • 5Goodman WK, Bose A, Wang Q, et al. Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials [J]. J Affect Disord, 2005, 87 (2/3) :161- 167.
  • 6Allgulander C, Hackett D, Salinas E . Venlafaxine extended release (ER) in the treatment of gener- alised anxiety disorder: twenty-four-week placebo- controlled dose-ranging study[J]. Br J Psychiatry, 2001, 179:15-22.
  • 7Davideson JR, Bose A, Kozotzer A, et al. Escitalo- pram in the treatment of generalized anxiety disor- der.. Double-blind, placebo controlled, flexible-dose study[J]. Depress Anxiety, 2004, 19 (4): 234- 240.
  • 8Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Ef- ficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder., a 6-month randomized controlled trial[J]. JAMA ,2000,283: 3082-3088.
  • 9Montgomery SA, Sheehan DV, Meoni P, et al. Char- acterization of the longitudinal course of improve- ment ingeneralized anxiety disorder during long- term treatment with venlafaxine XR[J]. J Psychiatr Res,2002,36(4) :209-217.
  • 10Bose A , Korotzer A, Gommoll C, et al, Random- ized placebo-controlled trial of escitalopram and ven- lafaxine XR in the treatment of generalized anxiety disorder[J]. Depress Anxiety, 2008,25 (10) : 854 - 861.

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部